Lee's Pharmaceutical Hldg Stock (OTC: LPCUF)

Latest news for Lee's Pharmaceutical Hldg (OTC:LPCUF) Stock

Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Biotech

Penny Stocks

General

AKBA

LPCUF

UNCY

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000 suffer from end-stage renal disease (ESRD). Of these, nearly 500,000 require dialysis to stay alive.

LEES PHARMA HLDGS LTD ORD by Lees Pharmaceutical Holdings Ltd

Lee's Pharmaceutical Holdings Ltd

News

UHAL

U-Haul Plans To Build A Retail, Moving And Self-Storage Center In Athens

Wolfe Research analyst Shweta Khajuria initiates coverage on Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Peer Perform rating.

Initiation

Analyst Ratings

SNAP

Wolfe Research Initiates Coverage On Snap with Peer Perform Rating

Contracts

GILT

Gilat Bags Over $5M From A National Defense Organization To Upgrade Transportable SATCOM Network Hubs

This consolidation is intended to enhance efficiency, improve alignment and improve process speed within SNDL&#39;s vertical model.

SNDL

SNDL Consolidates Its Cannabis Segments Into A Single Unit Under Leadership Of Tyler Robson

Wolfe Research analyst Shweta Khajuria initiates coverage on Yelp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) with a Peer Perform rating.

YELP

Wolfe Research Initiates Coverage On Yelp with Peer Perform Rating

Syngenta Partners With Ginkgo Bioworks To Boost The Launch Of Biologicals

GTEC

Greenland Technologies And Lonking Team Up To Develop U.S. Heavy Machinery Industry With HEVI Electric Equipment

The project is expected to deliver over&nbsp;$20 million&nbsp;in annualized cost savings driven primarily by the optimization of corporate overhead spending. The restructuring will require a one-time investment of&nbsp;$11 million&nbsp;over the next 18 months.
SNDL expects to achieve most of the anticipated annualized savings by mid-2025, while starting to capture some of the opportunities as early as&nbsp;Q3&nbsp;2024.

SNDL Plans Restructuring Project Aimed At Reducing Corporate Overheads; Reveals Reduction Of 106 Full-time Employees

Baird analyst Eric Coldwell maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Neutral and lowers the price target from $20 to $19.

Price Target

Baird Maintains Neutral on Owens & Minor, Lowers Price Target to $19

Wolfe Research analyst Shweta Khajuria initiates coverage on Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Outperform rating and announces Price Target of $90.

UBER

Wolfe Research Initiates Coverage On Uber Technologies with Outperform Rating, Announces Price Target of $90

Janus International Launches Two New Roll-Up NS Series Self-Storage Door Solutions

Jiyue, the electric vehicle (EV) manufacturer formed by Baidu, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) in collaboration with Geely Holding Group, is set to introduce its latest model, the <a target="_blank" href="https://www.benzinga.com/electric-vehicles" rel="noreferrer noopener">Jiyue 07 electric sedan, in September.</a>
The Jiyue 07, which follows the Jiyue 01 SUV as the second model under the Jiyue brand, is already on display at certain Jiyue showrooms, <a target="_blank" href="https://cnevpost.com/2024/07/16/jiyue-to-launch-jiyue-07-sept/" rel="noreferrer noopener">reported</a> CnEV Post.
The dimensions of the Jiyue 07 exceed those of Tesla&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Model 3.
The Model 3 measures 4,724 mm in length, 1,848 mm in width, and 1,430 mm in height, with a wheelbase of 2,875 mm. Comparatively, the Jiyue 07 measures 4,953 mm in length, 1,989 mm in width, and 1,475 mm in height, with a wheelbase of 3,013 mm.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39749573/nio-advances-vehicle-safety-with-ai-enhanced-automatic-emergency-braking-and-navigation-features" rel="noreferrer noopener">NIO Advances Vehicle Safety With AI-Enhanced Automatic Emergency Braking And Navigation Features In Latest Update</a>
According to a regulatory filing on May 11, the Jiyue 07 will be manufactured at Geely&#8217;s plant in Ningbo, Zhejiang province. It will be available in both single-motor and dual-motor configurations.
The single-motor version features an electric motor capable of delivering up to 200 kW of power, while the dual-motor version includes an additional front motor also capable of 200 kW, both supplied by Geely Auto&#8217;s affiliate Viridi E-mobility Technology.
The Jiyue 07 offers two choices of battery packs: 71.4 kWh and 100 kWh, sourced from suppliers such as CATL and Svolt Energy. It boasts a range of up to 880 kilometers on a single charge, with intermediate options of 660 kilometers and 770 kilometers, the report highlighted.
Originally named Jidu, the brand underwent a renaming to Jiyue after Geely and Baidu formed the joint venture in March 2021. Initially, Baidu held a 55% stake while Geely owned 45%. On August 15, 2023, Geely announced the rebranding to Jiyue, replacing Jidu, potentially due to regulatory considerations.
Jiyue unveiled the Jiyue 07 sedan for the first time at the Beijing Auto Show in late April 2024.
Price Action: BIDU shares are trading lower by 0.32% to $92.85 premarket at last check Tuesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by testing on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39755144/airbus-launches-lead-initiative-reportedly-aims-to-strengthen-aircraft-manufacturing-ahead-of-bo" target="_blank" rel="noreferrer noopener">Airbus Launches &#8216;LEAD!&#8217; Initiative, Reportedly Aims To Strengthen Aircraft Manufacturing Ahead Of Boeing&#8217;s Recovery</a></li>
</ul>

Equities

Markets

Media

BIDU

TSLA

Baidu-Backed Jiyue To Launch Jiyue 07 Electric Sedan In September; Larger Than Tesla Model 3: Report

Wolfe Research analyst Shweta Khajuria assumes Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Peer Perform rating.

RBLX

Wolfe Research Assumes Roblox at Peer Perform

Earnings

PNC Financial Services Q2 Net Interest Income Decreases To $3.302B Compared With $3.510B YoY; Q2 Noninterest Income Totals $2.109B Higher Than $1.783B YoY

Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) is scheduled to release its financial results for the second quarter, before the <a href="https://www.benzinga.com/quote/MS/earnings">opening bell on Tuesday, July 16.</a>
Analysts expect the New York-based company to report quarterly earnings at $1.65 per share, up from $1.24 per share in the year-ago period. Morgan Stanley expects to post revenue of $14.3 billion. It posted $13.08 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Morgan Stanley is set to launch an AI-powered assistant to enhance the workflow of its financial advisors. The AI assistant, named Debrief, will automate the note-taking process during client meetings, creating draft emails and summaries of the discussions, CNBC reported recently.
Morgan Stanley shares gained 1.1% to close at $105.26 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/MS/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Oppenheimer analyst Chris Kotowski maintained an Outperform rating and raised the price target from $101 to $105 on April 30. This analyst has an accuracy rate of 84%.</li>
<li>BMO Capital analyst James Fotheringham maintained an Outperform rating and boosted the price target from $115 to $118 on April 18. This analyst has an accuracy rate of 73%.</li>
<li>B of A Securities analyst Michael Carrier maintained a Buy rating and increased the price target from $100 to $106 on April 17. This analyst has an accuracy rate of 80%.</li>
<li>Keefe, Bruyette &amp; Woods analyst David Konrad maintained a Market Perform rating and raised the price target from $94 to $98 on April 17. This analyst has an accuracy rate of 75%.</li>
<li>CFRA analyst Kenneth Leon maintained a Buy rating and increased the price target from $97 to $108 on April 16. This analyst has an accuracy rate of 77%.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39770776/over-18m-bet-on-this-tech-stock-check-out-these-4-stocks-insiders-are-buying">Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

Morgan Stanley Likely To Report Higher Q2 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Earnings Beats

CORRECTION: Bank of America Q2 2024 GAAP EPS $0.83 Beats $0.80 Estimate, Sales $25.537B Beat $25.220B Estimate

Dividends

Bank of America Announced Plans For An 8% Increase In Quarterly Common Stock Dividend, To $0.26 Per Share, Pending Board Approval

Bank of America Q2 Consumer Banking Revenue $10.2B, Down 3%; Sales And Trading Revenue Up 9%, Total Investment Banking Fees Up 29%

Guidance

Health Care

ANGO

AngioDynamics Forecasts Fiscal Year 2025 Adjusted EPS Of $(0.38)-$(0.42), Compared To Fiscal 2024 Pro Forma Adjusted EPS Of $(0.45) Versus Consensus Of $(0.49)

CORRECTION: Bank of America Q2 Provision For Credit Losses $1.5B, Up From $1.1B YoY; Avg. Deposit Balances $1.91T, Up 2% (Corrects Quarter)

Lee's Pharmaceutical Hldg

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000 suffer from end-stage renal disease (ESRD). Of these, nearly 500,000 require dialysis to stay alive. In fact, each year, more people die from this silent killer than from breast or prostate cancer.&nbsp;

Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.&nbsp;

Uncontrolled phosphorus levels will often cause other complications like heart disease and bone fractures, increasing the risk of hospitalization by up to 38% and the risk of mortality by up to a staggering 102%. Even though there are six Food and Drug Administration (FDA)-approved drugs on the market to treat hyperphosphatemia, 75% of patients with hyperphosphatemia are unable to bring their phosphorus down to target levels Some of the currently available products include Auryxia, produced by Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), and Velphoro, from Fresenius Medical Care AG &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>).

As such, it would appear that the medications currently available on the market are unable to fully address the needs of the patient population. One company from California is looking to do its bit to help change that.

Will Their New Pill Help Solve This Growing Problem?

Unicycive Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>), a Los Altos, California company, is seeking to develop a solution that is more effective than its competitors. The company is developing a proprietary drug called RenazorbTM which is less than 2 years away from potential FDA approval, that binds and eliminates phosphate in the GI tract.&nbsp;

This new drug uses a patented nanoparticle technology that (if approved) Unicycive believes will more effectively reduce phosphorus to target levels. RenazorbTM also offers added convenience to patients because it is swallowed with water instead of having to be chewed.

Recently Unicycive <a href="https://www.globenewswire.com/en/news-release/2022/07/20/2482554/0/en/Unicycive-Reports-Key-Findings-from-Market-Research-with-Nephrologists.html">commissioned</a> a survey of nephrologists &mdash; doctors who specialize in kidney health &mdash; and found that their top concerns in managing hyperphosphatemia in their patients was the need for a lower pill burden and better patient compliance.&nbsp;

Many people suffering from hyperphosphatemia also have other comorbidities that require taking other pills, creating a high pill burden. This leads to 62% of patients self-reporting non-compliance &mdash; patients neglecting to take their medication because they are overwhelmed by the number and size of the pills that they must take and their side effects. &nbsp;

The efficiency and smaller size of RenazorbTM pills may reduce the pill burden for these patients by 3 to 4 fold. Accordingly, nephrologists say they would prescribe RenazorbTM (once approved) to 34% of their dialysis patients requiring phosphate binder therapy - this is a market-leading figure indicative of the levels of practitioner confidence in the promise for this new drug.

Notably, Unicycive also recently signed an agreement with Lee&rsquo;s Pharmaceutical (HK) Ltd., a subsidiary of Lee&rsquo;s Pharmaceutical Holdings Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LPCUF#OTC">LPCUF</a>), for exclusive distribution rights to RenazorbTM in China and other Asian markets.&nbsp;

The worldwide market for hyperphosphatemia drugs sits at over $2 billion (with over $1 bn of that being the U.S. market). It is expected to achieve a 5.3% compound annual growth rate between 2021 and 2028. Unicycive believes that this leaves the field wide open for a drug that will bring real solutions to patients suffering from inadequate and burdensome medicine for a persistent medical problem worldwide.&nbsp;

&ldquo;We were delighted to initiate our pivotal bioequivalence trial of Renazorb(&trade;), which keeps us on track to complete the study around year-end and to file a new drug application in 2023,&rdquo; said Unicycive CEO Shalaba Gupta. He also said that the agreement with Lee&rsquo;s Pharmaceutical &ldquo;underscores the potential for Renazorb(&trade;) as a best-in-class phosphate binder worldwide.&rdquo;

To learn more about the company, visit its website <a href="http://www.unicycive.com">www.unicycive.com</a>.&nbsp;

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Featured photo by <a href="https://stock.adobe.com/promo/firstmonthfree?gclid=CjwKCAjwyaWZBhBGEiwACslQo9eYmvRj2IhQdnD4FECHD4sjMjkAXhxx_VmuZC63yFGB4ULGCO_WRxoCtBgQAvD_BwE&amp;ef_id=CjwKCAjwyaWZBhBGEiwACslQo9eYmvRj2IhQdnD4FECHD4sjMjkAXhxx_VmuZC63yFGB4ULGCO_WRxoCtBgQAvD_BwE:G:s&amp;s_kwcid=AL!3085!3!435418461353!b!!g!!%2Badobe%20%2Bstock!10064798521!99429367645&amp;as_channel=sem&amp;as_campclass=brand&amp;as_campaign=US%7CCPRO%7CStock%7CPURCH%7CAS_Brand_BMM%7CGG%7C%7C&amp;as_source=google&amp;as_camptype=acquisition&amp;sdid=KQPCU&amp;mv=search&amp;as_audience=core">Adobe Stock</a>

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000 suffer from end-stage renal disease (ESRD). Of these, nearly 500,000 require dialysis to stay alive. In fact, each year, more people die from this silent killer than from breast or prostate cancer.&nbsp;

Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.&nbsp;

Uncontrolled phosphorus levels will often cause other complications like heart disease and bone fractures, increasing the risk of hospitalization by up to 38% and the risk of mortality by up to a staggering 102%. Even though there are six Food and Drug Administration (FDA)-approved drugs on the market to treat hyperphosphatemia, 75% of patients with hyperphosphatemia are unable to bring their phosphorus down to target levels Some of the currently available products include Auryxia, produced by Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), and Velphoro, from Fresenius Medical Care AG &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>).

As such, it would appear that the medications currently available on the market are unable to fully address the needs of the patient population. One company from California is looking to do its bit to help change that.

Will Their New Pill Help Solve This Growing Problem?

Unicycive Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>), a Los Altos, California company, is seeking to develop a solution that is more effective than its competitors. The company is developing a proprietary drug called RenazorbTM which is less than 2 years away from potential FDA approval, that binds and eliminates phosphate in the GI tract.&nbsp;

This new drug uses a patented nanoparticle technology that (if approved) Unicycive believes will more effectively reduce phosphorus to target levels. RenazorbTM also offers added convenience to patients because it is swallowed with water instead of having to be chewed.

Recently Unicycive <a href="https://www.globenewswire.com/en/news-release/2022/07/20/2482554/0/en/Unicycive-Reports-Key-Findings-from-Market-Research-with-Nephrologists.html">commissioned</a> a survey of nephrologists &mdash; doctors who specialize in kidney health &mdash; and found that their top concerns in managing hyperphosphatemia in their patients was the need for a lower pill burden and better patient compliance.&nbsp;

Many people suffering from hyperphosphatemia also have other comorbidities that require taking other pills, creating a high pill burden. This leads to 62% of patients self-reporting non-compliance &mdash; patients neglecting to take their medication because they are overwhelmed by the number and size of the pills that they must take and their side effects. &nbsp;

The efficiency and smaller size of RenazorbTM pills may reduce the pill burden for these patients by 3 to 4 fold. Accordingly, nephrologists say they would prescribe RenazorbTM (once approved) to 34% of their dialysis patients requiring phosphate binder therapy - this is a market-leading figure indicative of the levels of practitioner confidence in the promise for this new drug.

Notably, Unicycive also recently signed an agreement with Lee&rsquo;s Pharmaceutical (HK) Ltd., a subsidiary of Lee&rsquo;s Pharmaceutical Holdings Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LPCUF#OTC">LPCUF</a>), for exclusive distribution rights to RenazorbTM in China and other Asian markets.&nbsp;

The worldwide market for hyperphosphatemia drugs sits at over $2 billion (with over $1 bn of that being the U.S. market). It is expected to achieve a 5.3% compound annual growth rate between 2021 and 2028. Unicycive believes that this leaves the field wide open for a drug that will bring real solutions to patients suffering from inadequate and burdensome medicine for a persistent medical problem worldwide.&nbsp;

&ldquo;We were delighted to initiate our pivotal bioequivalence trial of Renazorb(&trade;), which keeps us on track to complete the study around year-end and to file a new drug application in 2023,&rdquo; said Unicycive CEO Shalaba Gupta. He also said that the agreement with Lee&rsquo;s Pharmaceutical &ldquo;underscores the potential for Renazorb(&trade;) as a best-in-class phosphate binder worldwide.&rdquo;

To learn more about the company, visit its website <a href="http://www.unicycive.com">www.unicycive.com</a>.&nbsp;

Image sourced from <a href="https://www.shutterstock.com/image-photo/lower-back-pain-man-holding-his-732789853">Shutterstock</a>

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lee's Pharmaceutical Hldg

News

Latest news for Lee's Pharmaceutical Hldg (OTC:LPCUF) Stock

Thursday, September 22, 2022